Section Arrow
Quote
SLXN.NASDAQ
- Silexion Therapeutics Corp
(Financial Status)
Quotes are at least 15-min delayed:2025/04/12 04:14 EDT
Last
 0.845
+0.021 (+2.55%)
Day High 
0.86 
Prev. Close
0.824 
1-M High
1.381 
Volume 
66.81K 
Bid
0.83
Ask
0.85
Day Low
0.8005 
Open
0.85 
1-M Low
0.7 
Market Cap 
7.16M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.92 
20-SMA 1.05 
50-SMA 1.18 
52-W High 122.0184 
52-W Low 0.575 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-26.36/-1.31
Enterprise Value
10.49M
Balance Sheet
Book Value Per Share
-0.46
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals5.76+1.25+27.72%-- 
THTXTheratechnologies1.94+0.61+45.86%-- 
CDTConduit Pharmaceuticals Inc0.9101-0.1599-14.94%-- 
PRTGPortage Biotech Inc8.59+3.49+68.43%0.17PE
HEPAHepion Pharmaceuticals0.422-0.0091-2.11%-- 
Quotes are at least 15-min delayed：2025/04/12 04:14 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulationof cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.